TL-532, the first rationally designed TLR3 agonist creates long-lasting tumor specific immunity in vivo
Sting & TLR-targeted therapies – May 2021 – Presented by Dr Bettina Werle
Tollys accelerates development of TLR3 agonist candidates for intravenous administration in immuno-oncology
Based on the strong preclinical data collected to date with locally administered TL-532, Tollys is accelerating and expanding its internal and collaborative R&D activities on TLR3 agonist candidates designed for intravenous administration and antibody-drug-conjugates.
Recent Comments